Key Highlights

  • Globe Life (NYSE:GL) reported third-quarter net operating income of USD 4.84 per share on Wednesday, October 21, 2026, against the consensus estimate of USD 4.89 and USD 4.81 a year earlier.
  • Life underwriting margin fell 5% to USD 458.2 million, or 53% of premium from 57%, while health premium grew 16% to USD 446.9 million and total premium rose 7%.
  • The company cited an Evry underwriting loss of about USD 16 million and about USD 7 million of excess Medicare Supplement claims linked to a federal claims processing delay.
  • Globe Life raised expected 2026 buybacks to USD 725 million to USD 775 million from USD 670 million to USD 700 million and guided 2026 net operating EPS of USD 15.35 to USD 15.65.

Premium Growth Against Thinner Life Margins

Globe Life (NYSE:GL), a McKinney, Texas-based life and supplemental health insurer, reported third-quarter results at 4:10 p.m. ET on Wednesday, October 21, 2026. Net operating income was USD 4.84 per share, against the consensus estimate of USD 4.89 and USD 4.81 a year earlier. Diluted EPS was USD 4.62, against USD 4.73, after realised investment losses of USD 0.13 a share and legal proceedings costs of USD 0.09. Total premium rose 7% to USD 1.31 billion. Life premium grew 2% to USD 864.6 million and health premium 16% to USD 446.9 million. The life underwriting margin fell to USD 458.2 million, or 53% of premium, from 57%. Health underwriting margin rose 7% to USD 115.6 million, though it slipped to 26% of premium from 28%.

Why One-Off Losses Weighed on Underwriting

Globe Life (NYSE:GL) earns most of its profit from underwriting margin, the premium left after policy benefits and acquisition costs. That margin includes remeasurement gains booked when the company updates its actuarial assumptions. This quarter the gain was USD 120.5 million, against USD 134.3 million a year earlier, and the life portion fell to USD 96.4 million from USD 130.9 million. The company also cited an underwriting loss of about USD 16 million at Evry and about USD 7 million of excess prior-period Medicare Supplement claims after a federal Medicare claims processing delay. It said the pressure did not reflect a fundamental change in its core business. Excess investment income, the investment return left after interest credited to policy reserves, rose 9% to USD 0.49 a share.

Risks and What to Watch

The first risk for Globe Life (NYSE:GL) is that life margins stay near 53% of premium if remeasurement gains keep shrinking. The second is distribution: American Income producing agents fell 7% to 11,331, and Direct to Consumer life net sales fell 12% to USD 24.0 million. The third is health claims timing, since delayed Medicare Supplement claims can land in later periods and distort quarterly margins. Liberty National offered an offset, with producing agents up 9% to 4,187 and life net sales up 7%. Investors should watch the earnings call at 11:00 a.m. ET on Thursday, October 22, 2026, progress on the raised buyback range and the 2027 net operating EPS estimate of USD 16.10 to USD 17.10.

Where Things Stand

The answer is that Globe Life (NYSE:GL) fell USD 0.05 short because life underwriting margin narrowed, with smaller remeasurement gains, an Evry loss and delayed Medicare Supplement claims all weighing. Premium still grew 7%, and book value per share rose 23% to USD 85.35. Management raised its buyback range and set a 2027 estimate implying about 7% growth at the midpoint. The next catalysts are the call on October 22 and the fourth-quarter report. Guidance is a company estimate, not a guarantee, and this is not investment advice.